Our top pick for
Akouos Inc is a biotechnology business based in the US. Akouos shares (AKUS) are listed on the NASDAQ and all prices are listed in US Dollars. Akouos employs 69 staff and has a market cap (total outstanding shares value) of 0.00.
|Latest market close||$9.18|
|52-week range||$9.39 - $22.82|
|50-day moving average||$11.53|
|200-day moving average||$12.46|
|Wall St. target price||$30.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.88|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-21)||-5.94%|
|1 month (2021-09-28)||-25.97%|
|3 months (2021-07-28)||-28.06%|
|6 months (2021-04-28)||-42.48%|
|1 year (2020-10-27)||-53.87%|
|2 years (2019-10-24)||N/A|
|3 years (2018-10-24)||N/A|
|5 years (2016-10-24)||N/A|
|Gross profit TTM||$0|
|Return on assets TTM||-11.75%|
|Return on equity TTM||-21.18%|
|Market capitalisation||$327.6 million|
TTM: trailing 12 months
There are currently 2.3 million Akouos shares held short by investors – that's known as Akouos's "short interest". This figure is 2.1% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting Akouos shares can be evaluated.
Akouos's "short interest ratio" (SIR) is the quantity of Akouos shares currently shorted divided by the average quantity of Akouos shares traded daily (recently around 94644.484995945). Akouos's SIR currently stands at 24.66. In other words for every 100,000 Akouos shares traded daily on the market, roughly 24660 shares are currently held short.
However Akouos's short interest can also be evaluated against the total number of Akouos shares, or, against the total number of tradable Akouos shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Akouos's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Akouos shares in existence, roughly 70 shares are currently held short) or 0.109% of the tradable shares (for every 100,000 tradable Akouos shares, roughly 109 shares are currently held short).
A SIR above 20% would generally be considered very high, pointing to a pessimistic outlook for the share price, with a discouraging number of investors currently willing to bet against Akouos.
Find out more about how you can short Akouos stock.
We're not expecting Akouos to pay a dividend over the next 12 months.
Akouos, Inc. , a precision genetic medicine company, developing gene therapies to restore, improve, and preserve physiologic hearing for individuals. The company's precision genetic medicine platform incorporates a proprietary adeno-associated viral vector library and a novel delivery approach. Its lead product candidate is AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene. The company is also developing AK-CLRN1 for the auditory manifestations of Usher syndrome 3A, or USH3A; and AK-antiVEGF for vestibular schwannoma. In addition, its precision genetic medicine platform addresses hearing loss related to genes needed for supporting cell function. Akouos, Inc.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.